NZ720241A - Viral vector manufacture - Google Patents

Viral vector manufacture

Info

Publication number
NZ720241A
NZ720241A NZ72024114A NZ72024114A NZ720241A NZ 720241 A NZ720241 A NZ 720241A NZ 72024114 A NZ72024114 A NZ 72024114A NZ 72024114 A NZ72024114 A NZ 72024114A NZ 720241 A NZ720241 A NZ 720241A
Authority
NZ
New Zealand
Prior art keywords
modified
cell
viral vector
cho
vector manufacture
Prior art date
Application number
NZ72024114A
Other languages
English (en)
Inventor
Paul Michael Howley
Liang Liu
Original Assignee
Sementis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904242A external-priority patent/AU2013904242A0/en
Application filed by Sementis Ltd filed Critical Sementis Ltd
Publication of NZ720241A publication Critical patent/NZ720241A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151Methods of production or purification of viral material
    • C12N2710/24152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ72024114A 2013-11-01 2014-11-03 Viral vector manufacture NZ720241A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013904242A AU2013904242A0 (en) 2013-11-01 Viral vector manufacture
AU2014900370A AU2014900370A0 (en) 2014-02-07 Orthopox vectors and propagation
PCT/AU2014/050330 WO2015061858A1 (en) 2013-11-01 2014-11-03 Viral vector manufacture

Publications (1)

Publication Number Publication Date
NZ720241A true NZ720241A (en) 2019-10-25

Family

ID=53003022

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ72024114A NZ720241A (en) 2013-11-01 2014-11-03 Viral vector manufacture

Country Status (24)

Country Link
US (2) US10544397B2 (enExample)
EP (2) EP3375882B1 (enExample)
JP (2) JP6682443B2 (enExample)
KR (1) KR102047030B1 (enExample)
CN (1) CN106255758B (enExample)
AU (1) AU2014344738B2 (enExample)
CA (1) CA2931518C (enExample)
CY (1) CY1121414T1 (enExample)
DK (2) DK3063278T3 (enExample)
ES (1) ES2670034T3 (enExample)
HR (1) HRP20180789T1 (enExample)
HU (1) HUE037718T2 (enExample)
LT (1) LT3063278T (enExample)
NO (1) NO3063278T3 (enExample)
NZ (1) NZ720241A (enExample)
PL (1) PL3063278T3 (enExample)
PT (1) PT3063278T (enExample)
RS (1) RS57290B1 (enExample)
RU (1) RU2658487C2 (enExample)
SG (1) SG11201603919XA (enExample)
SI (1) SI3063278T1 (enExample)
SM (1) SMT201800267T1 (enExample)
TR (1) TR201807128T4 (enExample)
WO (1) WO2015061858A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI728173B (zh) * 2016-08-19 2021-05-21 澳大利亞商賽門堤斯有限公司 病毒疫苗
JP2018081568A (ja) * 2016-11-17 2018-05-24 グローリー株式会社 紙幣収納装置および紙幣処理機
CA3258751A1 (en) * 2022-06-30 2024-01-04 Bavarian Nordic As Mammalian cell line for the production of modified Ankara vaccine virus (MVA)
EP4590841A2 (en) * 2022-09-20 2025-07-30 Aldevron, LLC Best1 vectors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604183B1 (fr) * 1986-09-23 1988-12-30 Transgene Sa Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
DE60336653D1 (de) * 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
AU2007280004A1 (en) * 2006-08-04 2008-02-07 Dublin City University A method of producing recombinant biological products

Also Published As

Publication number Publication date
SG11201603919XA (en) 2016-07-28
CY1121414T1 (el) 2020-05-29
CN106255758B (zh) 2020-06-23
JP2016534755A (ja) 2016-11-10
RU2658487C2 (ru) 2018-06-21
TR201807128T4 (tr) 2018-06-21
EP3063278A4 (en) 2017-04-12
CA2931518A1 (en) 2015-05-07
HUE037718T2 (hu) 2018-09-28
CN106255758A (zh) 2016-12-21
AU2014344738B2 (en) 2019-03-21
WO2015061858A1 (en) 2015-05-07
CA2931518C (en) 2021-03-09
EP3375882A1 (en) 2018-09-19
PT3063278T (pt) 2018-05-25
EP3375882B1 (en) 2019-10-16
DK3375882T3 (da) 2019-12-16
US20200190482A1 (en) 2020-06-18
RS57290B1 (sr) 2018-08-31
EP3063278A1 (en) 2016-09-07
DK3063278T3 (en) 2018-06-06
SMT201800267T1 (it) 2018-07-17
US20170029784A1 (en) 2017-02-02
RU2016121425A (ru) 2017-12-04
EP3063278B1 (en) 2018-02-28
AU2014344738A1 (en) 2016-06-09
PL3063278T3 (pl) 2018-08-31
KR20160079868A (ko) 2016-07-06
JP2020039340A (ja) 2020-03-19
ES2670034T3 (es) 2018-05-29
KR102047030B1 (ko) 2019-11-20
HK1223395A1 (en) 2017-07-28
SI3063278T1 (sl) 2019-04-30
NO3063278T3 (enExample) 2018-07-28
LT3063278T (lt) 2018-07-10
US10544397B2 (en) 2020-01-28
HRP20180789T1 (hr) 2018-09-07
JP6682443B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
IL281038A (en) Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy in hemophilia A
Cohen et al. An approach to abstract argumentation with recursive attack and support
ZA201907716B (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
MY187559A (en) Modified hepatitis post-transcriptional regulatory elements
PH12017501942A1 (en) Oncolytic adenovirus encoding a b7 protein
MX2016016100A (es) Determinacion de curvatura de vehiculos.
CA2906566C (en) Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
EA201400836A1 (ru) Получение дитерпена
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
MX351727B (es) Integracion especifica de sitio.
GB2519255A (en) Methods for genome assembly and haplotype phasing
MX2015011951A (es) Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.
EA201590888A1 (ru) Мутации флавивирусного белка оболочки, нарушающие разборку вириона
MX353499B (es) Sistema de expresion en cho.
TW201712486A (en) Trackpads and methods for controlling a trackpad
MX2018007352A (es) Moduladores de la actividad del complemento.
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
MX2016011300A (es) Vectores recombinantes del virus isfahan.
NZ720241A (en) Viral vector manufacture
ZA201803442B (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
BR112015017420A2 (pt) recombinação de vírus influenza
WO2014145968A3 (en) Rna interference functions as an antiviral immunity in mammals
MX2016012085A (es) Metodos para producir glucoproteinas recombinantes con glucosilacion modificada.
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2021 BY CPA GLOBAL

Effective date: 20200917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2022 BY CPA GLOBAL

Effective date: 20210916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2023 BY CPA GLOBAL

Effective date: 20220923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2024 BY CPA GLOBAL

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2026 BY DENNEMEYER + CO. SARL

Effective date: 20251028